Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2005
05/12/2005US20050100603 Sustained release pharmaceutical composition
05/12/2005US20050100602 Sustained release pharmaceutical composition
05/12/2005US20050100601 Virucidal activities of cetylpyridinium chloride
05/12/2005US20050100597 salt of diclofenac with tromethamine; gingivitis, glossitis, stomatitis, aphthae, paradentosis, paradentitis, laryngitis, pharyngitis, mucositis of the oral cavity caused by radiotherapy and chemotherapy
05/12/2005US20050100594 Tizanidine and valdecoxib for example; muscle relaxant is released in an extended release manner and a cyclooxygenase-2 inhibitor in immediate release form; treating pain, spasticity
05/12/2005US20050100589 Transdermal administration of ace inhibitors
05/12/2005US20050100585 Delivery system for topical medications
05/12/2005US20050100584 Composition for animal consumption
05/12/2005US20050100567 Liquid concentrate for the preservation of cosmetic and pharmaceutical products
05/12/2005US20050100564 Controlled release delivery system for nasal applications
05/12/2005US20050100538 Intradiscal injection of anti-oxidants
05/12/2005US20050100537 Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
05/12/2005US20050100536 Platelet rich plasma, no exogenous activator; sodium bicarbonate buffer, citrate dextrose anticoagulant
05/12/2005US20050100534 firoin and firoin-A from extremophilic microorganisms ; active protection and stabilization of skin cells and their organic constituents (proteins, enzymes, membranes, nucleic acids or antioxidants); against damaging environmental influences, UV radiation.
05/12/2005US20050100530 Medicinal composition
05/12/2005US20050100529 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione and anti-cancer agent, antibiotic, anti-inflammatory agent, steroid, cytokine, immunosuppressive agent
05/12/2005US20050100526 Antibiotic polymers
05/12/2005US20050100519 Glycolic acid, papain, arbutin are hydroxy acids, proteolytic enzymes, skin lightening agents optional to this skin care formulation
05/12/2005US20050100508 Contacting proliferating cells in vitro with an agent that reduces mitotic kinesin biological activity; inhibitor is an antisense compound or RNAi compound; cancer
05/12/2005US20050100506 Mechanism-based targeted pancreatic beta cell imaging and therapy
05/12/2005US20050098502 filtration of coal tar to remove impurities, then adding zinc pyrithione, surfactants and carriers to form mixtures used for the treatment of skin disorders
05/12/2005DE10197266T5 Verfahren zur örtlichen Betäubung und Schmerzstillung Method for local anesthesia and pain relief
05/12/2005CA2584969A1 Neuroprotection with beta-lactam compounds
05/12/2005CA2553156A1 Composition and dosage form for sustained effect of levodopa
05/12/2005CA2551074A1 Hcv ns3-ns4a protease resistance mutants
05/12/2005CA2546691A1 Once-a-day, oral, controlled-release, oxycodone dosage forms
05/12/2005CA2544781A1 Plant-derived .beta.3-adrenergic receptor agonist substances and uses thereof
05/12/2005CA2544772A1 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
05/12/2005CA2544763A1 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
05/12/2005CA2544731A1 Rapamycin peptides conjugates: synthesis and uses thereof
05/12/2005CA2544725A1 Vitamin d3 lactam derivative
05/12/2005CA2544377A1 Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
05/12/2005CA2544361A1 Method for the direct synthesis of oligorhamnosides, composition comprising oligorhamnosides and use thereof as a medicament
05/12/2005CA2544357A1 Tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
05/12/2005CA2544352A1 Crystalline anhydrate with anticholinergic effect
05/12/2005CA2544350A1 N-substituted benzene sulfonamides
05/12/2005CA2544348A1 Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
05/12/2005CA2544335A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
05/12/2005CA2544332A1 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
05/12/2005CA2544325A1 Imidazo [1,2-a] pyridine derivatives for the treatment of silent gastro-esophageal reflux
05/12/2005CA2544317A1 Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists
05/12/2005CA2544310A1 New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
05/12/2005CA2544307A1 Pharmaceutical compositions with synchronized solubilizer release
05/12/2005CA2544297A1 Use of 2-thia-dibenzo[e, h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
05/12/2005CA2544267A1 Thiazolidinones, production and use thereof as medicaments
05/12/2005CA2544190A1 Inhibitors of coronavirus protease and methods of use thereof
05/12/2005CA2544128A1 Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
05/12/2005CA2544107A1 Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
05/12/2005CA2544100A1 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
05/12/2005CA2544050A1 Use of plant parts of prickly pear (opuntia) and/or extracts therefrom for the treatment of depressions
05/12/2005CA2544049A1 Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof
05/12/2005CA2543945A1 Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
05/12/2005CA2543942A1 Indirubin-type compounds, compositions, and methods for their use
05/12/2005CA2543918A1 Benzimidazoles useful as modulators of ion channels
05/12/2005CA2543756A1 Hydroxypropyl amides for the treatment of alzheimer's disease
05/12/2005CA2543745A1 Methods of organ regeneration
05/12/2005CA2543716A1 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
05/12/2005CA2543715A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
05/12/2005CA2543710A1 Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
05/12/2005CA2543709A1 Non-effervescent form of sodium naproxen comprising i.a. sodium hydrogen carbonate
05/12/2005CA2543696A1 Combinations for hcv treatment
05/12/2005CA2543685A1 Neutrophil activation by immune response modifier compounds
05/12/2005CA2543649A1 Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
05/12/2005CA2543608A1 Pyrimidines as inhibitors of phosphoinositide -3-kinases (pi3k)
05/12/2005CA2543533A1 2-cyanopyrrolidinecarboxamide compound
05/12/2005CA2543530A1 Use of biocompatible polymers for the preparation of a composition or a medical device
05/12/2005CA2543522A1 Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
05/12/2005CA2543503A1 Combinations comprising an hsp90 inhibitor and a phophodiesterase inhibitor for treating or preventing neoplasia
05/12/2005CA2543458A1 Process for co-spray drying agents with dry silicified mcc
05/12/2005CA2543443A1 Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
05/12/2005CA2543438A1 Improved aza-bridged-bicyclic amino acid derivatives as a4 integrin antagonists
05/12/2005CA2543436A1 Spirofuropyridine aryl derivatives
05/12/2005CA2543346A1 Benzimidazolyl derivatives
05/12/2005CA2543345A1 Androgen receptor modulators
05/12/2005CA2543322A1 Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
05/12/2005CA2543252A1 Use of bh4 for the treatment of respiratory diseases
05/12/2005CA2543248A1 Process for making sterile aripiprazole of desired mean particle size
05/12/2005CA2543245A1 Transdermal pharmaceutical spray formulations comprising a vp/va copolymer and a non-aqueous vehicle
05/12/2005CA2543242A1 Controlled release sterile injectable aripiprazole formulation and method
05/12/2005CA2543238A1 Compositions and dosage forms for enhanced absorption
05/12/2005CA2543227A1 Administration of levodopa and carbidopa
05/12/2005CA2543216A1 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrozol-3-one choline
05/12/2005CA2543198A1 Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
05/12/2005CA2543187A1 Medicamentously targeted local lipolysis
05/12/2005CA2543185A1 Compositions and dosage forms for ehnanced absorption of iron
05/12/2005CA2543181A1 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
05/12/2005CA2543177A1 Compositions and dosage forms for enhanced absorption of metformin
05/12/2005CA2543170A1 Compositions and methods for increasing hdl and hdl-2b levels
05/12/2005CA2543144A1 Methods and compositions for identifying therapeutic compounds
05/12/2005CA2543142A1 Methods and compositions for identifying therapeutic compounds
05/12/2005CA2543135A1 Methods and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions
05/12/2005CA2543122A1 3-(4-aminophenyl) thienopyrimid-4-one derivatives as mch r1 antagonists for the treatment of obesity, diabetes, depression and anxiety
05/12/2005CA2543089A1 Dopamine-, norepinephrine- and serotonin- transporter- selective heterocyclic compounds and their therapeutic applications
05/12/2005CA2543087A1 Use of peroxisome proliferator-activated receptor gamma (ppar.gamma.) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions
05/12/2005CA2543012A1 Naphthalene-1,5-disulfonic acid salts of a substituted 4-amino-1-(pyridylmethyl)piperidine compound
05/12/2005CA2542995A1 Substituted heterocyclic compounds and methods of use
05/12/2005CA2542970A1 Prodrugs of diaryl-2-(5h)-furanone cyclooxygenase-2 inhibitors
05/12/2005CA2542904A1 Iap nucleobase oligomers and oligomeric complexes and uses thereof
05/12/2005CA2542884A1 Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent
05/12/2005CA2542880A1 Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy
1 ... 4694 4695 4696 4697 4698 4699 4700 4701 4702 4703 4704 4705 4706 4707 4708 4709 4710 4711 4712 4713 4714 ... 7860